Metastatic Prostate Cancer Market Report 2026

The metastatic prostate cancer market size has grown strongly in recent years. It will grow from $8.81 billion in 2025 to $9.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising incidence of advanced prostate cancer cases, expansion of oncology treatment centers, improved survival rates through early intervention, availability of multiple therapeutic options, increased use of chemotherapy protocols.

The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $13.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of novel immunotherapies, rising adoption of personalized cancer treatments, expansion of clinical trials for advanced therapies, growing use of radiopharmaceutical treatments, increasing focus on quality-of-life outcomes. Major trends in the forecast period include increasing adoption of targeted and hormonal therapies, rising use of combination treatment regimens, growing focus on precision oncology approaches, expansion of advanced diagnostic and biomarker testing, enhanced emphasis on patient-centered treatment strategies.

The growing demand for personalized treatments is expected to drive the growth of the metastatic prostate cancer market in the coming years. Personalized treatments are medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. This rising demand is driven by the increasing availability of genomic profiling and biomarker testing, which help identify specific mutations and biological markers, enabling clinicians to select therapies that are more likely to be effective for each patient. Personalized approaches, such as biomarker-guided therapies and gene-targeted drugs, are transforming metastatic prostate cancer management by aligning specific therapies with each patient’s unique tumor profile to enhance effectiveness and reduce side effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized treatments is fueling the growth of the metastatic prostate cancer market.

Leading companies in the metastatic prostate cancer market are focusing on technological advancements in cancer treatment, such as advanced targeted radioligand therapy, to deliver precise radiation to cancer cells while minimizing exposure to healthy tissue. Advanced targeted radioligand therapy combines a molecule that targets prostate-specific membrane antigen (PSMA) with a radioactive isotope, enabling selective destruction of cancer cells throughout the body. For instance, in March 2025, Novartis AG, a Switzerland-based multinational pharmaceutical company, received FDA approval for Pluvicto for earlier use in patients with PSMA-positive metastatic castration-resistant prostate cancer. Pluvicto consists of a PSMA-targeting ligand linked to a beta-emitting radionuclide; it works by binding to PSMA-expressing tumor cells and delivering localized radiation to destroy cancer cells. Key features include high tumor specificity, a favorable safety profile, and the potential to be combined with other therapies. Its applications span advanced-stage prostate cancer treatment, particularly in patients who have progressed after androgen deprivation therapy, with benefits including improved progression-free survival, targeted cytotoxicity, reduced off-target effects, and enhanced patient outcomes.

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals for $2.4 billion. Through this acquisition, AstraZeneca aims to expand its next-generation radioconjugate platform and accelerate the development of targeted cancer therapies, particularly for metastatic castration-resistant prostate cancer and other solid tumors. Fusion Pharmaceuticals is a Canada-based clinical-stage company specializing in targeted therapies, including potential treatments for metastatic castration-resistant prostate cancer (mCRPC).

Major companies operating in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Clarity Pharmaceuticals Ltd., Convergent Therapeutics Inc., Johnson & Johnson, Sanofi, Eli Lilly And Company, Roche Holding AG, Takeda Pharmaceutical Company Limited.

North America was the largest region in the metastatic prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the metastatic prostate cancer market by increasing costs of imported active pharmaceutical ingredients, biologics, diagnostic imaging equipment, and radiation therapy components. Oncology centers and hospitals in North America and Europe are most affected due to dependence on globally sourced oncology drugs and devices, while Asia-Pacific faces pricing pressure on treatment imports. These tariffs are increasing therapy costs and affecting patient access. However, they are also encouraging domestic drug manufacturing, regional clinical research investments, and localized production of oncology therapeutics.

The metastatic prostate cancer market research report is one of a series of new reports that provides metastatic prostate cancer market statistics, including metastatic prostate cancer industry global market size, regional shares, competitors with a metastatic prostate cancer market share, detailed metastatic prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic prostate cancer industry. This metastatic prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells have spread from the prostate gland to other parts of the body, such as bones, lymph nodes, or distant organs. This stage indicates disease progression beyond the prostate and guides treatment decisions aimed at slowing spread, relieving symptoms, and improving survival.

The primary treatment types for metastatic prostate cancer include chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and others. Chemotherapy uses potent drugs to kill fast-growing cells, including cancer cells, and is administered through routes such as oral, parenteral, intravenous, intrathecal, intraperitoneal, intra-arterial, and topical. These treatments are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by end users including hospitals, clinics, cancer centers, research laboratories, and others.

The metastatic prostate cancer market consists of sales of radiopharmaceuticals, biosimilars, cancer pain management drugs, diagnostic imaging agents, and supportive care medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.